Bluebird's $2.8 million gene therapy becomes most expensive drug after U.S. approval - Reuters

The U.S. Food and Drug Administration on Wednesday approved bluebird bio's <a href="https://www.reuters.com/companies/BLUE.O" target="_blank">(BLUE.O)</a> gene therapy for patients with a rare disorder requiring regular blood transfusions, and the drugmaker p…

Aug 17 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved bluebird bio's (BLUE.O) gene therapy for patients with a rare disorder requiring regular blood transfusions, and the dru… [+2050 chars]

full article...